GROWTH OPPORTUNITIES IN RNA THERAPEUTICS, CANCER THERAPEUTICS & DIAGNOSTICS, AND LUNG HEALTH

GROWTH OPPORTUNITIES IN RNA THERAPEUTICS, CANCER THERAPEUTICS & DIAGNOSTICS, AND LUNG HEALTH

RELEASE DATE
21-May-2021
REGION
Global
Research Code: D759-00-20-00-00
SKU: HC03415-GL-TA_25450

$950.00

Special Price $855.00 save 10 %

In stock
SKU
HC03415-GL-TA_25450

$950.00

$855.00 save 10 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) discusses antisense oligonucleotides-based therapy for treating cystic fibrosis, novel therapeutics for loculated pleural effusion, medicinal food to maintain lung health, and developing novel therapeutics with modified thioredoxin. The TOE also focuses on developing novel therapeutics based on targeted protein degradation, protein derived from alternative sources for pet wellness, a probiotic artisan ice cream to treat gastro-intestinal issues, exosome therapeutics for delivery of drugs/vaccines, and circular RNA therapeutics for genetic and autoimmune diseases.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Antisense oligonucleotides, cystic fibrosis, loculated pleural effusion, lung health, thioredoxin, targeted protein degradation, protein, probiotics, gastro-intestinal issues, exosome therapeutics, drug delivery, circular RNA therapeutics, genetic and autoimmune diseases, pet health

Table of Contents

INNOVATIONS IN LIFE SCIENCES, HEALTH & WELLNESS

  • SPLISENSE LTD., ISRAEL
  • APELLIS PHARMACEUTICALS INC., MA, US
  • DAIICHI SANKYO, JAPAN
  • CHIESI GLOBAL RARE DISEASES, ITALY
  • LUNG THERAPEUTICS, US
  • RESBIOTIC, US
  • ORPRO THERAPEUTICS, US
  • ROCHE, SWITZERLAND
  • AVISA DIAGNOSTICS, US
  • SYNAIRGEN PLC, UK
  • VERACYTE, US
  • VIOME, US
  • JOHNSON & JOHNSON, US
  • OMNI PET FOOD, UK
  • BIFIDICE S.P.A., CHILE
  • CODIAK BIOSCIENCES, US
  • ORNA THERAPEUTICS, US
  • NUVALENT, US

KEY CONTACTS

  • KEY CONTACTS
  • KEY CONTACTS (CONTINUED)
  • KEY CONTACTS (CONTINUED)
  • KEY CONTACTS (CONTINUED)
  • KEY CONTACTS (CONTINUED)
Related Research
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) discusses antisense oligonucleotides-based therapy for treating cystic fibrosis, novel therapeutics for loculated pleural effusion, medicinal food to maintain lung health, and developing novel therapeutics with modified thioredoxin. The TOE also focuses on developing novel therapeutics based on targeted protein degradation, protein derived from alternative sources for pet wellness, a probiotic artisan ice cream to treat gastro-intestinal issues, exosome therapeutics for delivery of drugs/vaccines, and circular RNA therapeutics for genetic and autoimmune diseases. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Antisense oligonucleotides, cystic fibrosis, loculated pleural effusion, lung health, thioredoxin, targeted protein degradation, protein, probiotics, gastro-intestinal issues, exosome therapeutics, drug delivery, circular RNA therapeutics, genetic and autoimmune diseases, pet health
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D759-00-20-00-00
Is Prebook No
Ti Codes D759